Clinical Trial Update: A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 two-part multiple-dose study evaluating the safety and effects of AZD3293 (lanabecestat) in healthy elderly vo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AZD3293

Snippet

Sponsor: AstraZeneca | Conditions: Healthy Elderly Volunteers, Mild-to-moderate Alzheimer's Disease Patients | Phase 1 | Status: COMPLETED